Lilly and Kowa Pharmaceuticals America, a subsidiary of Kowa Co., Ltd., have entered into a co-promotion agreement to commercialize Livalo (pitavastatin) in the U.S. and entered into a licensing agreement in Latin America. Livalo is a statin approved by the FDA in August 2009 for the treatment of primary hyperlipidemia and mixed dyslipidemia. Under the terms of the agreements, Kowa Pharmaceuticals America will receive an undisclosed upfront payment. Lilly and Kowa Pharmaceuticals America will...